Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

571 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Novel formulations and modes of delivery of levodopa.
Poewe W, Antonini A. Poewe W, et al. Among authors: antonini a. Mov Disord. 2015 Jan;30(1):114-20. doi: 10.1002/mds.26078. Epub 2014 Dec 5. Mov Disord. 2015. PMID: 25476691 Review.
IPX066 is a novel extended-release l-dopa capsule that has successfully completed phase III clinical trials while the l-dopa prodrug XP21279 and a gastric retention formulation ("accordion pill") are in earlier phases of clinical development. ...Intrajejunal infusio …
IPX066 is a novel extended-release l-dopa capsule that has successfully completed phase III clinical trials while the l-dopa prodrug …
Subcutaneous lisuride infusion in Parkinson's disease: clinical results using different modes of administration.
Stocchi F, Ruggieri S, Antonini A, Baronti F, Brughitta G, Bellantuono P, Bravi D, Agnoli A. Stocchi F, et al. Among authors: antonini a. J Neural Transm Suppl. 1988;27:27-33. doi: 10.1007/978-3-7091-8954-2_4. J Neural Transm Suppl. 1988. PMID: 3165437
Lisuride is a potent dopamine agonist drug, very soluble in water and can be administered subcutaneously. Many authors have shown that the subcutaneous infusion of lisuride can control fluctuations when applied in combination with oral levodopa as a 24 hour continuo …
Lisuride is a potent dopamine agonist drug, very soluble in water and can be administered subcutaneously. Many authors have shown tha …
n-Hexane-induced parkinsonism: pathogenetic hypotheses.
Pezzoli G, Antonini A, Barbieri S, Canesi M, Perbellini L, Zecchinelli A, Mariani CB, Bonetti A, Leenders KL. Pezzoli G, et al. Among authors: antonini a. Mov Disord. 1995 May;10(3):279-82. doi: 10.1002/mds.870100308. Mov Disord. 1995. PMID: 7651443
n-Hexane, similar hydrocarbons, and derivatives are common environmental pollutants and by-products of lipid peroxidation, and they may have a nigrotoxic effect like that of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. This report describes our second case of parkinsonism …
n-Hexane, similar hydrocarbons, and derivatives are common environmental pollutants and by-products of lipid peroxidation, and they may have …
Increased striatal glucose consumption in Sydenham's chorea.
Weindl A, Kuwert T, Leenders KL, Poremba M, Gräfin von Einsiedel H, Antonini A, Herzog H, Scholz D, Feinendegen LE, Conrad B. Weindl A, et al. Among authors: antonini a. Mov Disord. 1993 Oct;8(4):437-44. doi: 10.1002/mds.870080404. Mov Disord. 1993. PMID: 8232353
Positron emission tomography and 18F-fluorodeoxyglucose were used to measure the regional cerebral glucose consumption in a 15-year-old choreatic girl with classical Sydenham's chorea shortly after the onset of hyperkinetic movements and 5 months later after chorea had res …
Positron emission tomography and 18F-fluorodeoxyglucose were used to measure the regional cerebral glucose consumption in a 15-year-o …
Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
Antonini A, Schwarz J, Oertel WH, Pogarell O, Leenders KL. Antonini A, et al. Mov Disord. 1997 Jan;12(1):33-8. doi: 10.1002/mds.870120107. Mov Disord. 1997. PMID: 8990051

Patients were treated with a combination of levodopa and dopamine agonists. Data were compared with 10 healthy controls in the same age range. Initially, patients with PD showed a significant increase of RACLO uptake in the putamen compared with controls (p < 0.0

Patients were treated with a combination of levodopa and dopamine agonists. Data were compared with 10 healthy controls in the same a …
Preoperative indicators of clinical outcome following stereotaxic pallidotomy.
Kazumata K, Antonini A, Dhawan V, Moeller JR, Alterman RL, Kelly P, Sterio D, Fazzini E, Beric A, Eidelberg D. Kazumata K, et al. Among authors: antonini a. Neurology. 1997 Oct;49(4):1083-90. doi: 10.1212/wnl.49.4.1083. Neurology. 1997. PMID: 9339694
Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET.
Antonini A, Kazumata K, Feigin A, Mandel F, Dhawan V, Margouleff C, Eidelberg D. Antonini A, et al. Mov Disord. 1998 Mar;13(2):268-74. doi: 10.1002/mds.870130212. Mov Disord. 1998. PMID: 9539340
We found that a linear combination of caudate, lentiform, and thalamic values accurately discriminated APD from IPD patients (p < 0.0001). ...FDG/PET may be a useful adjunct to the clinical examination in the differential diagnosis of parkinsonism....
We found that a linear combination of caudate, lentiform, and thalamic values accurately discriminated APD from IPD patients (p < …
Positron emission tomographic studies in restless legs syndrome.
Trenkwalder C, Walters AS, Hening WA, Chokroverty S, Antonini A, Dhawan V, Eidelberg D. Trenkwalder C, et al. Among authors: antonini a. Mov Disord. 1999 Jan;14(1):141-5. doi: 10.1002/1531-8257(199901)14:1<141::aid-mds1024>3.0.co;2-b. Mov Disord. 1999. PMID: 9918358
Tolerability of paroxetine in Parkinson's disease: a prospective study.
Tesei S, Antonini A, Canesi M, Zecchinelli A, Mariani CB, Pezzoli G. Tesei S, et al. Among authors: antonini a. Mov Disord. 2000 Sep;15(5):986-9. doi: 10.1002/1531-8257(200009)15:5<986::aid-mds1034>3.0.co;2-i. Mov Disord. 2000. PMID: 11009210 Clinical Trial.
We assessed the tolerability of the SSRI antidepressant paroxetine (10-20 mg once per day) in 65 outpatients with PD and depression for a period of at least 3 months. ...Paroxetine is a safe and effective drug to treat depression in PD....
We assessed the tolerability of the SSRI antidepressant paroxetine (10-20 mg once per day) in 65 outpatients with PD and depression for a
Pramipexole-treated Parkinson's disease during pregnancy.
Mucchiut M, Belgrado E, Cutuli D, Antonini A, Bergonzi P. Mucchiut M, et al. Among authors: antonini a. Mov Disord. 2004 Sep;19(9):1114-5. doi: 10.1002/mds.20148. Mov Disord. 2004. PMID: 15372610
We describe the case of a woman affected by PD treated with pramipexole monotherapy during pregnancy. The child, born by caesarean delivery, is healthy, whereas motor disability of the mother progressively increased to the point that levodopa therapy was necessary....
We describe the case of a woman affected by PD treated with pramipexole monotherapy during pregnancy. The child, born by caesarean de …
571 results
Jump to page
Feedback